Trials / Completed
CompletedNCT02283177
A Safety and Tolerability Study of Crenolanib in Combination With Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia Patients With FLT3 Mutations
A Safety and Tolerability Trial of Crenolanib and Chemotherapy With Cytarabine and Anthracyclines in Patients With Newly Diagnosed Acute Myeloid Leukemia With FLT3 Activating Mutations
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 44 (actual)
- Sponsor
- Arog Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This pilot study is designed to evaluate the safety and tolerability of oral crenolanib besylate given sequentially during standard induction and consolidation chemotherapy in patients with newly diagnosed AML with FLT3 activating mutations.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | crenolanib | |
| DRUG | cytarabine | |
| DRUG | daunorubicin | |
| DRUG | idarubicin |
Timeline
- Start date
- 2015-01-01
- Primary completion
- 2019-12-01
- Completion
- 2019-12-01
- First posted
- 2014-11-05
- Last updated
- 2024-02-02
- Results posted
- 2024-02-02
Locations
9 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02283177. Inclusion in this directory is not an endorsement.